Related Experiment Video
Updated: Feb 16, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Protecting infants from respiratory syncytial virus (RSV) in Ireland: Impact of a national nirsevimab immunisation
Laura Paris1, Lisa Domegan2, Maureen O'Leary2
1European Centre for Disease Prevention and Control (ECDC) Fellowship Programme, Field Epidemiology path (EPIET), ECDC, Stockholm, Sweden; Health Service Executive- Health Protection Surveillance Centre, Ireland.
Insights
Ireland
Area of Science:
- Public Health
- Immunology
- Pediatrics
Background:
- Ireland introduced a national immunisation program for respiratory syncytial virus (RSV) in the 2024/2025 season.
- Infants born between September 2024 and February 2025 were eligible for nirsevimab, a long-acting monoclonal antibody for RSV prevention.
Purpose of the Study:
- To evaluate the effectiveness of the nirsevimab immunisation program in reducing RSV-related illness among eligible infants in Ireland.
Main Methods:
- A retrospective, population-based ecological study analyzed RSV cases and clinical outcomes in the 2024/2025 season.
- Compared 2024/2025 data with historical RSV seasons (2023/2024 and 2022/2023).
- Calculated averted cases, disease prevented fractions, and number needed to immunise (NNI) using adapted formulas.
Main Results:
- 83% of eligible infants received nirsevimab in the 2024/2025 season.
- RSV cases decreased by 68% compared to the 2023/2024 season and 64% compared to the 2022/2023 season.
- The program averted 1055 RSV cases, 459 emergency department visits, 437 hospitalizations, and 76 ICU admissions, with a disease prevented fraction of 74.5%.
Conclusions:
- Nirsevimab immunisation significantly reduced RSV-related morbidity in Irish infants during the 2024/2025 season.
- The findings support the continued use of nirsevimab and suggest potential expansion to older infant populations.
Background:
To reduce the burden of respiratory syncytial virus (RSV) in infants, Ireland implemented a national immunisation programme in the 2024/2025 season. Infants born between 1 September 2024 and 28 February 2025 were offered nirsevimab, a long-acting monoclonal antibody.
Aim:
To estimate the impact of the nirsevimab immunisation programme on RSV-related morbidity among eligible infants.
Methods:
We conducted a retrospective, population-based ecological study including infants born during the programme period. RSV case distribution and clinical outcomes in 2024/2025 were described and compared with historical data. Immunisation uptake was monitored weekly. Using immunisation effectiveness estimates, uptake and notification data of cases, we estimated averted cases, disease prevented fractions, and the number needed to immunise (NNI) to prevent one RSV-notified case, emergency department (ED) presentation, hospitalisation, and intensive care unit (ICU) admission applying adapted Machado et al. formulas.
Results:
In 2024/2025, 83% (22,444) eligible infants received nirsevimab. In total 360 laboratory confirmed RSV cases were notified in infants born between September and February, compared to 1142 during the same period of 2023/2024 (severe season) and 997 during 2022/2023 (mild season), representing a 68% and 64% reduction, respectively. 1055 (95%CI:1038-1071) RSV notified cases, 459 (95%CI: 452-467) ED presentations, 437 (95%CI:430-443) hospitalisations, and 76 (95%CI:74-78) ICU admissions were averted in the 2024/2025 birth cohort. Disease prevented fraction was 74.5% (95%CI:73.6-75.4). NNI to prevent one RSV-notified case, was 22 (95%CI:21-24), 51 (95%CI:47-55) for ED presentations, 54 (95%CI:50-58) for hospitalisations, and 309 (95%CI:249-369) for ICU admissions.
Conclusion:
Immunisation with nirsevimab significantly reduced RSV-related illness in Irish infants in 2024/2025, supporting its continued use and potential expansion to older infant groups.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
National Nursing Organizations I
National Nursing Organizations II
The AACN emphasizes a healthy work environment through six standards to achieve an optimal patient outcome. The standards are appropriate staffing, meaningful recognition, collaboration, authentic leadership, effective communication, and decision-making. In addition, AACN provides certification programs, webinars, journals, and...
What are Viruses?
Impact of Groups on Groups
Anatomy of Respiratory System II: Lower Respiratory Tract
The Larynx
It is located between the pharynx and the trachea, acts as a passageway for air, and hosts several critical structures, such as the epiglottis, vocal cords, and glottis. The epiglottis acts as a gateway, guiding food to the...

